Media Resources

2016

European CSOs Call for Rejection of EU Trade Secrets Directive

2015

Trilogue Negotiations on Commission’s Proposal for Trade Secrets Directive

Medicines Transparency Alliance (MeTA) Evaluation

Global Snakebite Initiative Appoints Health Action International as Secretariat

Multi-sectoral NGO Coalition Calls on Parliament to Defend Safeguards for Consumers, Journalists, Whistleblowers, Public Authorities and Workers

Empty Gestures – The EU’s Commitments to Safeguard Access to Medicines

HAI and MSF Report Shows European Commission’s Access to Medicines Commitments are ‘Empty Gestures’

EU medicines policy & access to medicines

Early Access to Medicines Marketing Authorisation Flexibilities Should Only Respond to Unmet Medical Needs, Must Protect Patient Safety

Direct Patient Reporting in the EU: A Snapshot of Reporting Systems in Seven Member States

Declaration of Public Interest Regarding Access to Imatinib (Glivec) in Colombia

Health Action International Opposes European Parliament’s ISDS Compromise in TTIP

EU Medicines Policy and Access to Medicines

HAI Sexual Harassment Policy

Health Action International Launches New Brussels Office

Health Action International Criticises JURI Support for EU Trade Secrets Directive Report

How TTIP Could Damage Access to Affordable Medicines in the European Union

Assessing the Nature, Extent and Impact of Regulation of Medicines Promotion

2014 Annual Report and Financial Statements

2014 Annual Report and Financial Statements

EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions

2014

Retention of Medicines Policy in DG Health a Victory for Public Health Advocates

EMA’s Final Policy on Access to Clinical Data: Proactive Access to Some Data, But Strings Attached

EU Pharmacovigilance Public Hearings Should Be As Transparent and Independent as in US

Trading Away Access to Medicines – Revisited

Europe Seeks to Expand Big Pharma Monopoly at Expense of Poor People, Warn NGOs Ahead of TTIP Talks (2014)

Public Health in Danger with Move of Pharmaceutical Policy to DG Enterprise and Industry

Mapping External Reference Pricing Practices for Medicines

Investor-State Dispute Settlement in EU-US Trade Deal Risks Access to Affordable Medicines

EMA’s New Policy on Access to Clinical Data – About to Privatise Pharmaceutical Knowledge?